News Release

Contacts:

Integra LifeSciences Holdings Corporation

John B. Henneman, III                   Maria Platsis
Executive Vice President                Senior Director of Corporate Development
Chief Administrative Officer            and Investor Relations
(609) 936-2481                          (609) 936-2333
jhenneman@Integra-LS.com                mplatsis@Integra-LS.com


                   Integra LifeSciences Announces Agreement to
                          Acquire the Miltex Companies


Plainsboro, New Jersey / April 20, 2006 -- Integra LifeSciences Holdings
Corporation (NASDAQ: IART) announced today that it has agreed to acquire the
shares of Miltex, Inc. ("Miltex") for approximately $101 million in cash,
subject to certain adjustments.

Miltex, based in York, Pennsylvania, is a leading provider of surgical and
dental hand instruments to alternate site facilities, which includes physician
and dental offices and ambulatory surgery care sectors. Its distribution network
and service management team is recognized for providing the industry's highest
levels of customer service. Miltex generated revenues of $62 million and
operating EBITDA of $13 million for the year ending December 31, 2005.

"We are excited to bring Miltex into the Integra family. It will be an excellent
strategic fit with our instrument business and will enhance our cash flow and
profitability. Miltex will also provide us with a broader platform on which to
grow our business, as it participates in the alternate site, dental and
veterinary markets," said Stuart M. Essig, Integra's President and Chief
Executive Officer. "Miltex has more than fifty years of continuous service
through its distributor network and is already well positioned in each of these
markets," Mr. Essig added.

Miltex has an experienced senior management team with a long track record in the
surgical instrument business. After the closing of the acquisition, which
Integra anticipates to be in the second quarter, the management of Miltex will
join the leadership team at Integra. The company name will remain unchanged.

T. Robert Perrett, President of Miltex, said "Integra will be a good fit with
our business. Integra has its own excellent surgical instrument business for the
hospital markets and will offer us additional knowledge and resources to develop
new and innovative products and to provide our customers with unparalleled
service. These capabilities will afford Miltex the opportunity to continue its
company mission of `Redefining Excellence' and provide the ultimate level of
service to the healthcare providers who utilize our products."

Miltex sells the Miltex(R), Meisterhand, Vantage, Moyco, Union Broach, and
Thompson products in over 65 countries, using a network of independent
distributors. Integra will acquire Miltex's manufacturing and distribution
facility in York, Pennsylvania, which employs approximately 200 employees.
Miltex also operates a leased facility in Tuttlingen, Germany, where Miltex's
staff coordinates design, production and delivery of instruments. After closing,
Miltex will continue to manufacture and ship its products from York,
Pennsylvania.



Completion of the transaction is subject to customary closing conditions,
regulatory approvals and expiration of the requisite waiting period under the
Hart-Scott-Rodino Antitrust Improvements Act, as amended.

This acquisition is expected to be neutral to Integra's earnings for the
remainder of 2006, and accretive to Integra's earnings thereafter. Integra
expects to provide detailed guidance regarding the financial aspects of the
transaction, including the impact of purchase accounting, and its expected
impact on Integra's future financial results on its first quarter earnings
conference call scheduled for May 8, 2006.

Miltex is a portfolio company of American Securities Capital Partners, L.P., a
private equity firm in New York that pursues investments in partnership with
management teams in companies with leading market positions servicing attractive
industries.

American Securities Capital Partners, LLC ("ASCP") originated as the
merchant-banking arm of American Securities, L.P., which was founded in 1947 by
the late William Rosenwald to manage his share of his family's Sears Roebuck
fortune. ASCP makes equity investments in profitable companies, both privately
and publicly held, partnering with existing management teams to increase value
in the enterprises. Investments are funded from more than $2 billion of
committed capital that ASCP manages for its investor partners.

Integra LifeSciences Holdings Corporation is a diversified medical technology
company that develops, manufactures, and markets medical devices for use in a
variety of applications. The primary applications for our products are
neurosurgery, reconstructive surgery and general surgery. Integra is a leader in
applying the principles of biotechnology to medical devices that improve
patients' quality of life. Our corporate headquarters are in Plainsboro, New
Jersey, and we have manufacturing and research facilities located throughout the
world. We have approximately 1,400 employees. Please visit our website at
(http://www.Integra-LS.com).

This news release contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Forward-looking statements
include, but are not limited to, statements concerning expectations for this
newly acquired business and the expected impact of this acquisition on Integra's
future financial results. Such forward-looking statements involve risks and
uncertainties that could cause actual results to differ materially from
predicted or expected results. Among other things, Integra's ability to
successfully integrate Miltex into its operations could affect the impact of
this acquisition on Integra's future financial results. In addition, the
economic, competitive, governmental, technological and other factors identified
under the heading "Factors That May Affect Our Future Performance" included in
the Business section of Integra's Annual Report on Form 10-K for the year ended
December 31, 2005 and information contained in subsequent filings with the
Securities and Exchange Commission could affect actual results.

Source: Integra LifeSciences Holdings Corporation